Capvaxive

Capvaxive is a vaccine designed to protect against pneumococcal infections. It contains pneumococcal polysaccharides conjugated to CRM197, targeting specific serotypes. This vaccine is administered intramuscularly and is manufactured by Merck Sharp & Dohme B.V.

Capvaxive is used to prevent infections caused by pneumococcal bacteria. It is particularly aimed at protecting against serotypes included in the vaccine formulation. This vaccine is part of immunization programs to reduce the risk of pneumococcal diseases, which can affect the lungs, bloodstream, and other parts of the body.

After receiving Capvaxive, individuals may experience common effects such as soreness at the injection site, mild fever, or fatigue. These effects are typically temporary and resolve on their own. Severe reactions are rare but should be reported to a healthcare professional.

Before receiving Capvaxive, inform your healthcare provider about any allergies or medical conditions. It is important to follow the recommended schedule for vaccination. Individuals with weakened immune systems should consult their healthcare provider for personalized advice.

Capvaxive may interact with other medications or vaccines. It is advisable to discuss all current medications with a healthcare provider before receiving this vaccine. Avoid taking other vaccines simultaneously unless advised by a healthcare professional.